Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

What’s new in metastatic breast cancer?

What’s new in metastatic breast cancer? Overall, breast cancer mortality has declined due to advances in systemic adjuvant treatment in recent years; still, metastatic breast cancer remains an incurable disease. Due to novel treatment options, however, survival was prolonged even in patients with advanced-stage disease. In hormone-receptor positive breast cancer, endocrine therapy is the mainstay of treatment. Currently, different strategies are being evaluated to overcome resistance to anti-hormonal interventions, with the aim to prolong the chemotherapy-free interval. In Her2-positive breast cancer, anti-Her2 targeted therapies such as trastuzumab or lapatinib have improved patients’ outcome. Further substances—antibodies or novel tyrosine-kinase inhibitors—will increase therapeutic options in the future. Limited progress was achieved in the triple-negative sub-type. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is currently the only biological agent available in this sub-type. In combination with paclitaxel or capecitabine, bevacizumab offers clinically meaningful activity in metastatic breast cancer patients. Other strategies, such as treatment with DNA-damaging agents or the inhibition of DNA-repair mechanisms were not successful so far in a general triple-negative population. This article reviews recent developments and future trends in the field of metastatic breast cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

What’s new in metastatic breast cancer?

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/what-s-new-in-metastatic-breast-cancer-7t1WMLQjGG
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0004-5
Publisher site
See Article on Publisher Site

Abstract

Overall, breast cancer mortality has declined due to advances in systemic adjuvant treatment in recent years; still, metastatic breast cancer remains an incurable disease. Due to novel treatment options, however, survival was prolonged even in patients with advanced-stage disease. In hormone-receptor positive breast cancer, endocrine therapy is the mainstay of treatment. Currently, different strategies are being evaluated to overcome resistance to anti-hormonal interventions, with the aim to prolong the chemotherapy-free interval. In Her2-positive breast cancer, anti-Her2 targeted therapies such as trastuzumab or lapatinib have improved patients’ outcome. Further substances—antibodies or novel tyrosine-kinase inhibitors—will increase therapeutic options in the future. Limited progress was achieved in the triple-negative sub-type. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is currently the only biological agent available in this sub-type. In combination with paclitaxel or capecitabine, bevacizumab offers clinically meaningful activity in metastatic breast cancer patients. Other strategies, such as treatment with DNA-damaging agents or the inhibition of DNA-repair mechanisms were not successful so far in a general triple-negative population. This article reviews recent developments and future trends in the field of metastatic breast cancer.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: May 26, 2012

References

  • Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    Brewster, AM; Hortobagyi, GN; Broglio, KR
  • Extending survival with chemotherapy in metastatic breast cancer
    O’Shaughnessy, J.
  • Third consensus on medical treatment of metastatic breast cancer
    Beslija, S; Bonneterre, J; Burstein, HJ
  • Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the TEAM pathology sub-study
    Bartlett, JMS; Brookes, CL; van de Velde, CJH
  • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    Johnston, S; Pippen, J; Pivot, X
  • Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
    Osborne, CK; Neven, P; Dirix, LY
  • Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
    Baselga, J; Semiglazov, V; van Dam, P
  • Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
    Gianni, L; Lladó, A; Bianchi, G
  • Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA)
    Schneeweiss, A; Chia, S; Hickish, T
  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Gianni, L; Pienkowski, T; Im, YH
  • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Baselga, J; Cortés, J; Kim, SB
  • Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
    Burris III, HA; Rugo, HS; Vukelja, SJ
  • Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G)
    Perez, EA; Dirix, L; Kocsis, J
  • Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer.
    Cortés-Funes, H; Mendiola, C; Manso, L; Ciruelos, E
  • A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer
    Martin, M; Bonneterre, J; Geyer Jr, CE
  • Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab.
    Hickish, T; Wheatley, D; Lin, N
  • Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-Arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC)
    Gianni, L; Bianchini, G; Kiermaier, A
  • Association of PTEN loss and PIK3CA mutations on outcome in HER2+ metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
    Xu, B; Guan, Z-Z; Shen, Z-Z
  • Angiogenic factors
    Folkman, J; Klagsbrun, M
  • HER2 (neu) signaling increases the rate hypoxia-induceable factor 1α (HIF-1 α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    Laughner, E; Taghavi, P; Chiles, K; Mahon, PC; Semenza, GL
  • First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
    Gianni, L; Romieu, G; Lichinitser, M
  • Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)
    Bergh, J; Greil, R; Voytko, N
  • Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC)
    Crown, J; Dieras, V; Staroslawska, E
  • SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC)
    Baselga, J; Roche, H; Costa, F
  • Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer
    Birgisdottir, V; Stefansson, OA; Bodvarsdottir, SK; Hilmarsdottir, H; Jonasson, JG; Eyfjord, JE
  • Hallmarks of “BRCAness” in sporadic cancers.
    Turner, N; Tutt, A; Ashworth, A
  • Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer
    Gelmon, KA; Hirte, HW; Robidoux, A
  • Platinum-based chemotherapy in triple-negative breast cancer
    Sirohi, B; Arnedos, M; Popat, S
  • Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
    Byrski, T; Huzarski, T; Dent, R
  • NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Serra, V; Markman, B; Scaltriti, M
  • The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (BALI-1)
    Baselga, J; Gomez, P; Awada, A
  • Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
    Hankinson, SE; Willett, WC; Colditz, GA
  • Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    Nahta, R; Yuan, LX; Zhang, B; Kobayashi, R; Esteva, FJ
  • The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention
    Citri, A; Kochupurakkal, BS; Yarden, Y
  • HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Modi, S; Stopeck, A; Linden, H
  • A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
    Wiedermann, U; Wiltschke, C; Jasinska, J
  • A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer
    Mohebtash, M; Tsang, KY; Madan, RA
  • Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models
    Lobell, RB; Omer, CA; Abrams, MT
  • A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
    Johnston, SR; Semiglazov, VF; Manikhas, GM